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Abstract
Objective: To identify novel CSF biomarkers in GRN-associated frontotempo-
ral dementia (FTD) by proteomics using mass spectrometry (MS). Methods:
Unbiased MS was applied to CSF samples from 19 presymptomatic and 9
symptomatic GRN mutation carriers and 24 noncarriers. Protein abundances
were compared between these groups. Proteins were then selected for validation
if identified by ≥4 peptides and if fold change was ≤0.5 or ≥2.0. Validation and
absolute quantification by parallel reaction monitoring (PRM), a high-resolu-
tion targeted MS method, was performed on an international cohort (n = 210)
of presymptomatic and symptomatic GRN, C9orf72 and MAPT mutation carri-
ers. Results: Unbiased MS revealed 20 differentially abundant proteins between
symptomatic mutation carriers and noncarriers and nine between symptomatic
and presymptomatic carriers. Seven of these proteins fulfilled our criteria for
validation. PRM analyses revealed that symptomatic GRN mutation carriers had
significantly lower levels of neuronal pentraxin receptor (NPTXR), receptor-
type tyrosine-protein phosphatase N2 (PTPRN2), neurosecretory protein VGF,
chromogranin-A (CHGA), and V-set and transmembrane domain-containing
protein 2B (VSTM2B) than presymptomatic carriers and noncarriers. Symp-
tomatic C9orf72 mutation carriers had lower levels of NPTXR, PTPRN2,
CHGA, and VSTM2B than noncarriers, while symptomatic MAPT mutation
carriers had lower levels of NPTXR and CHGA than noncarriers. Interpreta-
tion: We identified and validated five novel CSF biomarkers in GRN-associated
FTD. Our results show that synaptic, secretory vesicle, and inflammatory pro-
teins are dysregulated in the symptomatic stage and may provide new insights
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into the pathophysiology of genetic FTD. Further validation is needed to inves-
tigate their clinical applicability as diagnostic or monitoring biomarkers.
Introduction
Frontotemporal dementia (FTD) is the second most com-
mon form of presenile dementia, with autosomal domi-
nant inheritance in approximately 30% of the cases.1,2
Pathogenic mutations in granulin (GRN) are a major
cause of hereditary FTD with underlying transactive
response DNA-binding protein 43 (TDP-43) pathology.2
The vast majority of GRN mutations result in reduction
of progranulin (PGRN) protein levels in blood and cere-
brospinal fluid (CSF) by haploinsufficiency.3–6 However,
the exact mechanism by which PGRN reduction leads to
neurodegeneration is poorly understood. Upcoming ther-
apeutic interventions should ideally be applied in the
presymptomatic or prodromal stage of the disease, when
neuronal damage is minimal, highlighting the need for
biomarkers that reflect early pathologic processes.7
Most studies on fluid biomarkers in FTD have used
targeted approaches, allowing measurement of known
protein candidates only,7,8 while unbiased approaches
have scarcely been performed.9,10 In autosomal dominant
Alzheimer’s disease, unbiased approaches have uncovered
early changes in the proteome.11
In the present study, we investigated CSF proteomics
by unbiased mass spectrometry (MS) in presymptomatic
and symptomatic GRN mutation carriers. We aimed to
identify novel proteins that reflect disease activity and/or
give insight into the pathophysiology. We validated and
quantified a selection of the identified proteins using par-
allel reaction monitoring (PRM), a high-resolution tar-
geted MS-based approach, in an international cohort of
GRN mutation carriers and other forms of genetic FTD,
namely C9orf72 and MAPT mutation carriers.1
Methods
Subjects
Discovery proteomics was applied on CSF of 9 symp-
tomatic and 19 presymptomatic GRN mutation carriers
and 24 healthy noncarriers (“discovery cohort”), who par-
ticipate in the Dutch longitudinal FTD Risk Cohort
(FTD-RisC).12 Briefly, patients with genetic FTD and
asymptomatic 50% at-risk individuals (either presymp-
tomatic mutation carriers or noncarriers) from families
with genetic FTD are followed yearly or two-yearly by
means of neurological examination, neuropsychological
testing, MRI scanning, structured informant interviews,
and collection of blood and, in a subset, CSF collection.
PRM was performed on a selection of the proteins
identified by discovery proteomics in CSF of 61 GRN
mutation carriers (31 presymptomatic, 30 symptomatic),
70 C9orf72 mutation carriers (16 presymptomatic, 54
symptomatic), 27 MAPT mutation carriers (12 presymp-
tomatic, 15 symptomatic), and 52 noncarriers (“validation
cohort”). CSF samples were collected from six research cen-
ters in Europe and the USA. Forty-six samples in the vali-
dation cohort overlapped with those in the discovery
cohort.
The study was approved by the local ethics committee
and all participants (or a legal representative) provided
written informed consent.
ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 699
E. L. van der Ende et al. CSF Proteomics in Genetic Frontotemporal Dementia
Sample collection
CSF was collected in polypropylene tubes according to
standardized local procedures and stored at 80°C after
centrifugation within 2 h after withdrawal.
Discovery proteomics
Discovery proteomics was performed as described previ-
ously13 and details are reported in Data S2. In short,
albumin and IgG were depleted from 50 ll of CSF sample
to maximize peptide detection (Pierce, PN 85162). After
overnight in-solution trypsin digestion, samples were ana-
lyzed by LC–MS/MS in a randomized order on a nano
LC system coupled to an Orbitrap Fusion Lumos mass
spectrometer (Thermo Fisher Scientific). For peptide and
protein identification, MS/MS spectra were extracted
using ProteoWizard14 software (version 3.0.9248) and
analyzed with the database search engine Mascot (Matrix
Science, UK) against the Uniprot database15 (downloaded
November 12, 2015; taxonomy: Homo sapiens; 20,194
entries). Next we combined the search results of the indi-
vidual samples, applied scoring of hits (local false discov-
ery rate ≤1%), and conducted protein grouping using the
software Scaffold.16,17 For label-free quantitation MS raw
data were processed with Progenesis QI (version 2.0) and
linked with identification results to finally determine
peptide and protein abundances. Abundances were nor-
malized to the total ion current to compensate for experi-
mental variations using an algorithm available in the
analysis software. Subsequently, the data were exported in
Excel format.
Statistical analyses of discovery proteomics
For all peptides identified by discovery proteomics, we
compared peptide abundances in: (1) symptomatic muta-
tion carriers versus noncarriers; (2) symptomatic versus
presymptomatic mutation carriers; (3) presymptomatic
mutation carriers versus noncarriers. As the data were not
normally distributed, a Wilcoxon rank-sum test was used.
Corresponding proteins were regarded as significantly dif-
ferentially abundant when they satisfied all of the follow-
ing criteria, as described before18 with minor adjustments:
(1) the protein was identified by two or more peptides;
(2) 25% or more of the peptides of the protein were sig-
nificant at P < 0.01; (3) 50% or more of the peptides of
the protein were significant at P < 0.05; (4) 75% or more
of the peptides were changed in the same direction (i.e.,
up- or downregulated). Statistical background levels were
determined by permutation tests on all samples and all
identified peptides/proteins. The number of differentially
abundant proteins was regarded as significant when the
observed number in the true analysis exceeded the thresh-
old from the permutation analysis: mean + three times
the standard deviation. Fold changes based on median
abundances were calculated for all group comparisons on
peptide levels and peptides with a median of zero were
excluded. Next, protein fold changes were calculated by
the mean of corresponding peptide fold changes.
PRM validation
Differentially abundant proteins from discovery pro-
teomics were selected for PRM validation based on the
following criteria: (1) the protein was identified by four
or more peptides and (2) protein fold change was ≤0.5 or
≥2.0.
PRM was essentially performed as described previ-
ously19 and details are reported in Data S2. In short,
20 lL of CSF was digested overnight by trypsin. LC-MS
analysis was carried out on a nano LC system coupled to
an Orbitrap Fusion mass spectrometer (Thermo Fisher
Scientific). For PRM of the peptide panel of candidates a
time scheduled targeted MS/MS method was used and
the referring peptide-specific parameters are listed in
Table S1. To allow absolute quantification of peptides,
synthetic stable isotope labeled (SIL) peptides were added
as listed in Table S1. As technical quality check (QC), a
pool of 80 CSF samples was prepared and loaded as
8-fold replicate on each well-plate. During LC-MS mea-
surements, every 12th run a QC sample was measured to
determine the reproducibility of the assay. For assessment
of sensitivity of the assay an eight-point dilutions series
of the peptide panel in CSF digest matrix was prepared
and measured in triplicate. MS data processing was con-
ducted using the software package Skyline.20 Peak ratios
were exported and used for calculation of CSF concentra-
tions of the samples and determining analytical parame-
ters limit of detection (LOD), lower limit of quantitation
(LLOQ), and coefficients of variance (CV) (Tables S2a
and S2b) using the software package R.21
Statistical analyses of demographic data
and PRM validation
Statistical analyses were performed in IBM SPSS Statistics
24.0 applying a significance level of P < 0.05. Demo-
graphic and PRM data for each genotype (GRN, C9orf72,
and MAPT) were compared between symptomatic muta-
tion carriers, presymptomatic mutation carriers, and non-
carriers. For PRM results, per candidate protein one
corresponding targeted peptide was chosen based on the
suitability for quantification and lowest LOD, LLOQ, and
CV as indicated in Tables S2a and S2b. Peptides with CV
>15% were excluded from further analyses. As the data
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were not normally distributed, a Kruskall-Wallis test with
post hoc Dunn’s test was performed to compare peptide
concentrations between groups. Analysis of covariance
(ANCOVA) of log-transformed peptide concentrations
was used to correct for age at CSF sampling. All post hoc
analyses were adjusted for multiple testing by means of
Bonferroni correction.
Mass spectrometry data has been made available via
the PRIDE partner repository with the dataset identifiers
PXD012178 (discovery study) and PXD012179 (validation
study).22
Gene set enrichment analyses
Gene set enrichment analyses to the Gene Ontology data-
base23 were performed on a selection of proteins identi-
fied by discovery proteomics in symptomatic mutation
carriers versus noncarriers, and separately on proteins
identified in symptomatic versus presymptomatic muta-
tion carriers. We relaxed the protein selection criteria to
allow for separation of multiple enriched pathways in our
dataset, aiming to include 50–150 proteins per enrich-
ment analysis. Proteins with a fold change ≤0.83 or ≥1.2
and with ≥25% of the peptides significantly up- or down-
regulated (P < 0.05) were included. Enrichment was per-
formed to the whole genome as statistical background,
accepting false discovery rate (FDR)-corrected results of
P < 0.05 as significantly enriched Gene Ontology (GO)
terms. The most significant nonredundant terms for Bio-
logical Processes (GOBP), Cellular Components (GOCC),
and Molecular Functions (GOMF) were extracted and a
protein network was created based on these terms using
Cytoscape (v3.4.0).
Results
Subjects
Subject characteristics are shown in Table 1. In the dis-
covery cohort, no differences were found in age at CSF
collection or gender among symptomatic and presymp-
tomatic mutation carriers and noncarriers. In the valida-
tion cohort, symptomatic GRN (median 61 years) and
C9orf72 mutation carriers (59 years) were significantly
older than presymptomatic GRN (54 years) and C9orf72
mutation carriers (45 years, both P < 0.001) and noncar-
riers (54 years, P < 0.001) at the time of CSF collection.
Discovery proteomics
We identified a total of 4539 peptides corresponding to
572 proteins, of which 503 proteins were identified by ≥2
peptides. Twenty proteins were considered significantly
differentially abundant in symptomatic GRN mutation
carriers compared to noncarriers. In the comparison
between symptomatic and presymptomatic GRN mutation
carriers, nine differentially abundant proteins were found
(Fig. 1, Table S3). No significant differences were found
between presymptomatic GRN mutation carriers and
noncarriers. All differentially abundant proteins were
identified by peptides, which were matched exclusively to
that protein.
Validation by PRM
Seven proteins fulfilled our criteria for validation by PRM
(Table 2). The protein Ig alpha-1 chain C region (IGHA1)
Table 1. Subject characteristics.
N
Age at CSF
collection, years Gender, male (%)
Age at symptom
onset, years Disease duration, years
Discovery cohort
Noncarriers 24 51 (40–58) 14 (58%) n/a n/a
Presymptomatic GRN 19 56 (47–60) 9 (47%) n/a n/a
Symptomatic GRN 9 58 (53–60) 3 (33%) 57 (51–58) 2.3 (1.5–3.6)
Validation cohort
Noncarriers 52 54 (43–59) 24 (46%) n/a n/a
Presymptomatic GRN 31 54 (42–59) 12 (39%) n/a n/a
Symptomatic GRN 30 61 (57–66)* 11 (37%) 58 (55–63) 1.9 (1.2–3.0)
Presymptomatic C9orf72 16 45(36–52) 3 (19%) n/a n/a
Symptomatic C9orf72 54 59 (54–65)† 31 (57%)‡ 56 (50–62) 2.4 (1.2–5.2)
Presymptomatic MAPT 12 48 (44–53) 5 (42%) n/a n/a
Symptomatic MAPT 15 53 (51–60) 7 (47%) 51 (46–55) 3.0 (1.4–5.0)
Continuous variables are presented as medians (interquartile range). FTD, frontotemporal dementia; CSF, cerebrospinal fluid.
*Symptomatic GRN mutation carriers significantly older than presymptomatic GRN mutation carriers and noncarriers (P < 0.001).
†Symptomatic C9orf72 mutation carriers significantly older than presymptomatic C9orf72 mutation carriers and noncarriers (P < 0.001).
‡Symptomatic C9orf72 mutation carriers and noncarriers significantly more males than presymptomatic C9orf72 mutation carriers (P = 0.024).
ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 701
E. L. van der Ende et al. CSF Proteomics in Genetic Frontotemporal Dementia
was excluded from validation analyses as just one peptide
was targeted and this peptide had a CV>15%.
Symptomatic GRN mutation carriers had significantly
lower concentrations of Neuronal pentraxin receptor
(NPTXR), Receptor-type tyrosine-protein phosphatase
N2 (PTPRN2), Neurosecretory protein VGF (VGF),
Chromogranin-A (CHGA), and V-set transmembrane
domain-containing protein (VSTM2B) compared to
both presymptomatic carriers and noncarriers by PRM
(Table 3, Fig. 2, Fig. S1). Complement component C8
gamma chain (C8G) levels were higher in symptomatic
mutation carriers, however, this difference was no longer
statistically significant after correction for age at CSF
sampling.
Entire dataset
19 presymptomatic GRN carriers 
9 symptomatic GRN carriers
24 non-carriers
4539 peptides
572 proteins
503 proteins identified 
by ≥2 peptides
Symptomatic vs. non-carriers
Decreased ↓
- Profilin-1
- Ig α-1 chain C 
region
- Complement C8-γ
- 14-3-3-ζ/δ
- 14-3-3-ε
- NPTXR
- PTPRN2
- Neurosecretory protein VGF
- Chromogranin-A
- CaM-kinase II α
- VSTM2B
- Cell growth regulator EF hand 1
- Proline-rich transmembrane 3
- Protein shisa-6 homolog
- CD99 antigen-like 2
- TNF receptor superfamily 21
- 45 kDa calcium-binding protein
- Golgi membrane protein 1
- Reelin
Symptomatic vs. presymptomatic
Decreased ↓Increased ↑
- Profilin-1
- 14-3-3-γ
- 14-3-3-ε
- CD44 antigen
- NPTXR
- Calsyntenin-3
- PTPRN
- Proline-rich 
transmembrane 3
- Polyubiquitin-BDifferentially
abundant proteins
Candidate 
biomarkers 
None - NPTXR - Ig α-1 chain C 
region
- Complement C8-γ
- NPTXR
- PTPRN2
- Neurosecretory protein VGF
- Chromogranin-A
- VSTM2B
Increased ↑
Figure 1. Flow chart of differentially abundant proteins. The number of identified peptides and proteins are displayed and are then split to the
differentially abundant proteins per group comparison: (1) symptomatic versus presymptomatic carriers, and (2) symptomatic versus noncarriers.
No differentially abundant proteins were found in the comparison presymptomatic versus noncarriers (not shown). In the lower row, proteins are
displayed that were selected for validation by PRM. CaM, Calcium/calmodulin-dependent; NPTXR, neuronal pentraxin receptor; PTPRN, receptor-
type tyrosine-protein phosphatase-like N; PTPRN2, receptor-type tyrosine-protein phosphatase N2; TNF, tumor necrosis factor; VSTM2B, V-set and
transmembrane domain-containing protein 2B.
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Symptomatic C9orf72 mutation carriers had significantly
lower concentrations of NPTXR, PTPRN2, CHGA, and
VSTM2B compared to noncarriers (Fig. 2, Fig. S1). Lower
concentrations of NPTXR, PTPRN2, CHGA, and VSTM2B
were found in presymptomatic mutation carriers than in
noncarriers, although not statistically significant.
Symptomatic MAPT mutation carriers had significantly
lower concentrations of NPTXR and CHGA compared to
noncarriers, while the other proteins did not show any
significant differences between groups (Fig. 2, Fig. S1).
For all proteins included in validation analyses, no sig-
nificant differences were found between presymptomatic
carriers and noncarriers.
Gene set enrichment analyses
For gene set enrichment analyses, 116 proteins were
included in the comparison of symptomatic mutation
carriers versus noncarriers, and 72 proteins were included
in the comparison of symptomatic versus presymptomatic
mutation carriers. In total, 44 GOBP and 7 GOCC terms
were significantly enriched (Data S1). The most signifi-
cantly enriched terms for both comparisons included
acute inflammatory response, response to axonal injury
and modulation of synaptic transmission. The generated
protein interaction network is shown in Figure S2.
Discussion
In this proteomics study, we identified several differen-
tially regulated proteins in CSF of GRN-associated FTD.
Validation of our results by targeted mass spectrometry
revealed significantly lower levels of NPTXR, CHGA,
VSTM2B, PTPRN2, and VGF in symptomatic GRN muta-
tion carriers compared to presymptomatic and noncarri-
ers. Here, we provide some background information on
these proteins.
NPTXR is a transmembrane protein expressed on neu-
rons and glia and is a member of the neuronal pentraxin
(NP) family. NPs are multifunctional proteins that have
been implicated in synaptic plasticity.24,25 NPTXR has
been identified as a progression biomarker in Alzheimer’s
disease (AD), with elevated levels in mild cognitive
impairment and low levels in AD patients.26–29 In autoso-
mal dominant AD, NPTXR levels were elevated in
presymptomatic carriers,11 an effect we did not observe in
our presymptomatic GRN carriers. This discrepancy may
result from differences in underlying pathophysiology, or
Table 2. Proteins selected for validation by PRM.
Peptides, n
Fold change
(SYM/NC)
Fold change
(SYM/PRE)
NPTXR 6 0.34 0.39
PTPRN2 5 0.35 –
VGF 21 0.45 –
CHGA 18 0.46 –
VSTM2B 4 0.49 –
C8G 4 2.00 –
IGHA1 6 2.39 –
Fold change (SYM/NC): fold change in discovery proteomics in the
comparison between symptomatic GRN mutation carriers and noncar-
riers. Fold change (SYM/PRE): fold change in discovery proteomics in
the comparison between symptomatic and presymptomatic GRN
mutation carriers. NPTXR, neuronal pentraxin receptor; PTPRN2,
receptor-type tyrosine-protein phosphatase N2; VGF, neurosecretory
protein VGF; CHGA, chromogranin-A; VSTM2B, V-set and transmem-
brane domain-containing protein 2B; C8G, complement component
C8 gamma chain; IGHA1, Ig alpha-1 chain C region.
Table 3. Protein levels measured by PRM in GRN mutation carriers.
Symptomatic carriers
(ng/ml) [IQR] (n = 30)
Presymptomatic carriers
(ng/ml) [IQR] (n = 31)
Noncarriers (ng/ml) [IQR]
(n = 52) P-value
NPTXR 89.1 [68.3–117.2] 138.2 [114.2–171.0] 148.4 [118.2–167.0] <0.001*
PTPRN2 8.7 [6.6–10.8] 15.1 [12.1–17.7] 13.6 [10.9–17.2] <0.001**
VGF 117.6 [78.3–167.9] 203.3 [158.4–273.0] 171.7 [129.5–228.9] <0.001†
CHGA 286.5 [233.6–343.6] 409.2 [293.6–471.9] 416.0 [337.7–509.6] <0.001*
VSTM2B 13.6 [11.0–16.2] 17.7 [13.6–21.3] 17.7 [15.4–21.9] <0.001‡
C8G 14.2 [10.2–20.6] 13.0 [9.2–17.5] 10.0 [7.9–15.6] 0.126
Peptides used for quantification are indicated in Table S2. P-values for analyses of covariance (correcting for age at CSF sampling) and after cor-
rection for multiple testing are displayed. NPTXR, neuronal pentraxin receptor; PTPRN2, receptor-type tyrosine-protein phosphatase N2; VGF, neu-
rosecretory protein VGF; CHGA, chromogranin-A; VSTM2B, V-set and transmembrane domain-containing protein 2B; C8G, complement
component C8 gamma chain.
*Symptomatic GRN mutation carriers versus noncarriers P < 0.001; symptomatic versus presymptomatic GRN mutation carriers P < 0.001.
**Symptomatic GRN mutation carriers versus noncarriers P = 0.002; symptomatic versus presymptomatic GRN mutation carriers P < 0.001.
†Symptomatic GRN mutation carriers versus noncarriers P = 0.045; symptomatic versus presymptomatic GRN mutation carriers P = 0.005.
‡Symptomatic GRN mutation carriers versus noncarriers P = 0.002; symptomatic versus presymptomatic GRN mutation carriers P = 0.007.
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because we studied presymptomatic carriers of all ages
and thus of varying time from onset.
VGF and CHGA belong to the granin protein family
and are precursors of peptides with numerous biological
functions, including microglial activation (CHGA) and
synaptic plasticity.30–32 Decreased VGF and CHGA levels
were also found in proteomics studies in AD.11,26,29,33
PTPRN2 is a transmembrane protein present in dense-
core vesicles, implicated in secretory processes in the pan-
creatic islets, but also in the brain.34 PTPRN, a highly
homologous protein, was also found in our discovery
proteomics, although it did not strictly fulfill our criteria
for validation (fold change 0.56). PTPRN2 is also
involved in secretory processes and is decreased in CSF of
AD patients.28 Both PTPRN2 and PTPRN also play more
general roles in secretion of hormones and neurotrans-
mitters, and knockdown of both these proteins result in
behavioral and learning impairments in mice.34
C8G, a constituent of innate immunity was elevated in
symptomatic GRN mutation carriers compared to noncar-
riers, although not statistically significant after correction
for covariates.35 An important role for inflammatory
pathways in FTD is supported by prior studies that iden-
tified YKL-40, complement factors and interleukines as
candidate biomarkers for FTD. The numerous enriched
gene ontology terms related to inflammatory processes
support this hypothesis. PGRN is implicated as an anti-
inflammatory protein, with haploinsufficiency resulting in
lysosomal dysfunction, complement production and
microglial activation.36
The last candidate protein we identified is VSTM2B,
this is a membrane protein but its exact function has
scarcely been studied.
The observed decrease in synapse proteins could repre-
sent synaptic turnover or loss occurring during the course
of the disease. Increasing evidence suggests that altered
synaptic function may contribute to the early pathogene-
sis of FTD, especially in GRN mutations,36–38 a concept
previously recognized primarily in AD. In rat hippocam-
pal neurons, knocking down PGRN decreases synapse
density,39 and in GRN-knockout mice, PGRN-deficiency
causes synaptic dysfunction prior to the occurrence of
other neuropathological changes.40 It has been hypothe-
sized that PGRN deficiency could cause synaptic prun-
ing through activation of microglia and complement
factors.36 Strategies aimed at increasing or maintaining
synaptic connectivity could prove beneficial in future
therapeutic interventions.
Four of the five protein decreases (NPTXR, VSTM2B,
CHGA, and PTPRN2) observed in symptomatic GRN car-
riers were also seen in symptomatic C9orf72 carriers,
suggesting that these changes are not specific for GRN-
associated FTD. The trend toward lower levels of these
proteins in presymptomatic C9orf72 carriers compared to
noncarriers, must be interpreted with caution due to the
lack of statistical significance. However, if confirmed in a
larger genetic FTD cohort, this could support the hypoth-
esis that C9orf72-associated FTD has a more protracted
onset than GRN-associated FTD.41–43 In MAPT mutation
carriers, significant differences in protein concentrations
were only found for NPTXR and CHGA. This may reflect
differences in underlying pathophysiology or it may be
due to the smaller sample size in MAPT mutation
carriers.2,7
Strengths of this study include the unique sample set
with a large cohort of presymptomatic and symptomatic
GRN mutation carriers. Restricting our discovery cohort
to GRN mutation carriers allowed us to create a patho-
logically homogeneous group of FTD-patients. The unbi-
ased proteomics approach enabled us to identify novel
biomarkers without predefined hypotheses. Validation of
our discovery proteomics results by PRM has provided
convincing evidence for our findings.
The depletion step in the discovery proteomics, remov-
ing albumin, and IgG, has considerably improved the
detection of low abundancy proteins. Very low abundancy
proteins could, however, be below the detection limit
despite the depletion step. This may explain why we did
not find PGRN, known to be decreased in GRN mutation
carriers, or neurofilament light chain (NfL), known to be
increased in symptomatic carriers, both of which have aver-
age CSF concentrations below 10 ng/ml.4,41 Furthermore,
relevant proteins may bind to the depleted proteins,
Figure 2. Neuronal pentraxin receptor (NPTXR) in presymptomatic
and symptomatic GRN, C9orf72 and MAPT mutation carriers by PRM.
Error bars represent medians with interquartile ranges. Significances
from the analysis of covariance (corrected for age at CSF sampling)
and after correction for multiple testing are displayed. *P < 0.05;
**P < 0.01; ***P < 0.001.
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thereby impeding their detection.44 Finally, our stringent
selection criteria for validation likely reduced the number
of false-positive findings, however, may also have excluded
certain relevant potential biomarkers.
In conclusion, we present five promising novel CSF
biomarkers in genetic FTD. Further verification and corre-
lation with clinical features is needed in larger cohorts of
genetic FTD, such as GENFI (Genetic FTD Initiative) and
LEFFTDS (Longitudinal Evaluation of Familial Frontotem-
poral Dementia Subjects). Validation by immunoassays is
necessary to reveal whether clinical implementation of
these biomarkers is feasible.
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